Related Experiment Videos
Porcine factor VIII: past, present and future.
1University Dept. of Haematology, Manchester Royal Infirmary, UK. haemophilia@man.ac.uk
Haematologica
|February 24, 2001
Summary
A new porcine factor VIII concentrate offers improved safety and efficacy for treating bleeds. This advanced product minimizes side effects and viral risks compared to current treatments.
Area of Science:
- Hematology
- Biotechnology
- Pharmaceutical Sciences
Background:
- Porcine factor VIII concentrate effectively treats bleeds in up to 90% of cases.
- Current porcine factor VIII use is linked to adverse reactions, including thrombocytopenia, and lacks viral attenuation.
- No viral transmission has been documented from this product to humans.
Purpose of the Study:
- To introduce a third-generation porcine factor VIII concentrate currently under development.
- To highlight the enhanced purification and viral attenuation methods.
- To project improved safety and reduced side effects.
Main Methods:
- Purification of porcine factor VIII from parvovirus-free plasma.
- Utilizing immunoaffinity and ion-exchange chromatography for purification.
- Employing the solvent detergent method for viral attenuation.
Main Results:
- The new concentrate is expected to be highly purified and virally attenuated.
- It is anticipated to possess very high specific activity.
- The product is expected to be virtually free of porcine von Willebrand factor.
Conclusions:
- The third-generation porcine factor VIII concentrate promises enhanced product safety.
- This development aims to significantly reduce the risk of treatment-related side effects.
- Further research will validate the clinical benefits of this advanced hemophilia treatment.